On 6 July, Abbott won FDA approval for its next-generation Gallant implantable cardioverter-defibrillator (ICD) and cardiac resynchronisation therapy defibrillator (CRT-D) devices, equipped with Bluetooth technology and accompanying smartphone app.
The ongoing outbreak of Covid-19 has highlighted the advancement of healthcare, pushing innovation for patient-centred care and seamless communication of health information between the patient and provider. By connecting to a smartphone app via Bluetooth, the app is designed to make communication between doctors and patients more efficient, enhancing remote monitoring capabilities.
